Search results
Results from the WOW.Com Content Network
These are rare and aggressive liver cancers, yet are the third most common primary liver cancer making up 0.1-2.0% of primary liver cancer. [22] Angiosarcoma and hemangiosarcoma of the liver come from the blood vessel's endothelial layer. These tumors have poor outcomes because they grow rapidly and metastasise easily.
Barcelona Clinic Liver Cancer classification [50] [51] [52] Stage Description Child-Pugh class ECOG performance status 0 (very early stage) Single nodule, < 3 cm: A: 0 A (early stage) 1–3 nodule, all < 3 cm: A or B B (intermediate stage) Multi-nodular tumor C (advanced stage) Portal invasion and extra-hepatic spread: 1 or 2 D (terminal stage ...
Hepatic arterial infusion (HAI) is a medical procedure that delivers chemotherapy directly to the liver.The procedure, mostly used in combination with systemic chemotherapy, plays a role in the treatment of liver metastases in patients with colorectal cancer (CRC). [1]
Mometasone, also known as mometasone furoate, is a steroid (specifically, a glucocorticoid) medication used to treat certain skin conditions, hay fever, and asthma. [ 10 ] [ 11 ] [ 12 ] Specifically it is used to prevent rather than treat asthma attacks. [ 10 ]
FLC accounts for 1–10% of primary liver cancers. [24] It typically has a young age at presentation when compared to conventional HCC. Previously it was estimated to be 20–40 years, mean ages 27 years, [ 25 ] but when analysis is restricted to those patients who are confirmed with a molecular test to have FLC, the age range is 10-40 and mean ...
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. [2] Symptoms of cholangiocarcinoma may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever. [1]
Hepatic artery embolization, also known as trans-arterial embolization (TAE), is one of the several therapeutic methods to treat primary liver tumors or metastases to the liver. The embolization therapy can reduce the size of the tumor, and decrease the tumor's impact such its hormone production, effectively decreasing symptoms.
In 2014, TMMC Cancer was invested in by the Japanese Sojitz Corporation [4] and its medical partner, Capita Medica, to develop a strategic Center of Excellence. [ 5 ] [ 6 ] The project was initiated by Dr. Dilshaad Ali, founding President and Group Chief Executive Director, and Tran Quoc Bao, the Group Business Development Director.